Leukemia Clinical Trials in Cleveland

Showing 781-800 of 802 trials

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

NCT00064285

RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with flavopiridol may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of flavopiridol and imatinib mesylate in treating patients with hematologic cancer.

Leukemia

Virginia Commonwealth University22 participantsStarted Jun 2003

Baltimore, Maryland, United States • Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States +1 more locations

COMPLETEDPHASE1/PHASE2< 1 mile

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

NCT00086099

The primary objectives of this study are: 1. To evaluate whether the addition of amifostine will allow for the safe administration of idarubicin at a dose of 21 mg/m² in combination with standard-dose ara-C in older patients with newly diagnosed, previously untreated acute myeloid leukemia (AML); and 2. To estimate the complete remission rate of induction therapy with amifostine, idarubicin (21 mg/m²), plus ara-C or induction therapy with idarubicin (12 mg/m²) plus ara-C in this patient population.

LeukemiaAcute Myeloid Leukemia

MedImmune LLC54 participantsStarted Jul 2004

San Diego, California, United States • Chicago, Illinois, United States • New Albany, Indiana, United States +16 more locations

Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Leukemia Trials in Other Cities

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Amonafide in Combination With Cytarabine in Secondary AML

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Other Conditions in Cleveland